Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-CP6A
- Development stage
- Phase 1
- Lead developer
- Shenzhen Boruijian Pharmaceutical
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
18F-CP6A is a fluorine-18 labeled positron emission tomography (PET) imaging agent designed to target and bind to aggregated α-synuclein protein in the brain. It is being developed as a diagnostic radiopharmaceutical for the detection and evaluation of synucleinopathies, including Parkinson's disease, Lewy body disease, and multiple system atrophy. The compound is a derivative of CP6A, itself an optimized version of F0502B—a small molecule with high affinity and selectivity for α-synuclein aggregates. By binding specifically to pathological α-synuclein deposits (Lewy bodies), 18F-CP6A enables visualization via PET imaging, potentially aiding early diagnosis and subtyping of neurodegenerative diseases characterized by synuclein pathology. Preclinical studies have demonstrated good safety profiles in animal models[1][2][5].
- Other names
- 18F-CP6A PET Imaging
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on 18F-CP6A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-CP6A.